Form 4: Immunovant CFO Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4
Eva Renee Barnett, CFO of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
Summary
- On April 9, 2025, Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., sold 7,013 shares of Immunovant's common stock at a weighted average price of $12.99.
- An additional 4,050 shares were sold at the same weighted average price on the same day.
- These sales were executed to cover tax withholding obligations associated with the vesting of 13,744 RSUs granted on April 2, 2024, and 8,938 RSUs granted on October 15, 2021.
- The sales were mandated by Immunovant's policy to cover tax obligations through 'sell to cover' transactions and do not represent discretionary transactions by the CFO.
- Following these transactions, Barnett directly owns 399,767 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations and does not reflect a change in the CFO's outlook on the company.
Industry Context
Sales of shares to cover tax obligations upon RSU vesting are a common practice among company executives. This transaction is not necessarily indicative of the CFO's sentiment towards the company's future prospects, as it is driven by tax obligations.
Comparison to Industry Standards
- Similar 'sell to cover' transactions are common among executives at publicly traded companies like Amgen, Regeneron, and Biogen when RSUs vest.
- The percentage of shares sold to cover taxes typically aligns with the executive's tax bracket and the company's policy on RSU settlements.
Stakeholder Impact
- The sale of shares may have a minor, temporary impact on the stock price due to the increased selling volume.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2021-10-15 | Grant date of 143,000 restricted stock units (RSUs). |
| 2024-04-02 | Grant date of 54,978 restricted stock units (RSUs). |
| 2025-04-02 | 13,744 RSUs vested from the April 2, 2024 grant. |
| 2025-04-04 | 8,938 RSUs vested from the October 15, 2021 grant. |
| 2025-04-09 | Date of share sales to cover tax obligations. |
| 2025-04-11 | Date of signature on the Form 4 filing. |
Keywords
Immunovant, Eva Renee Barnett, CFO, Form 4, Share Sale, RSU Vesting, Tax Withholding, IMVT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.